[草甘与膀癌的关联:一个快速回顾]
Laila Schneidewind1,2, Barbara Sommerhalder3, Dario Willi3
1Universitätsklinik für Urologie, Universität Bern, Inselspital Bern, Bern, Schweiz. laila.schneidewind@insel.ch.
Urologie (Heidelberg, Germany)
|March 11, 2025
概括
格利塔和膀癌风险之间的联系尚不清楚. 虽然注意到Nectin4的上调,但目前的证据是模两可的,没有被证明的因果关系和需要进一步研究的潜在治疗益处.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 作为口服抗糖尿病药物使用的glitazones因其增加膀癌风险或进展的潜力而受到争议.
- 最近的发现表明,glitazones可能会上调Nectin4的表达,这是一种涉及细胞粘附和癌症的蛋白质.
研究的目的:
- 进行快速的证据分析,以澄清glitazones与膀癌之间的关系.
- 确定系统审查和翻译研究,检查这种关联及其分子基础.
主要方法:
- 通过PubMed在MEDLINE的文献搜索,进行了快速的证据分析.
- 搜索覆盖了2000年7月 (glitazone欧盟批准) 到2024年7月15日的时间段.
主要成果:
- 包括14项研究:6项系统性审查 (5项具有元分析) 和8项翻译研究.
- 系统性审查显示,由于研究异质性和混因素,关于glitazones和膀癌的数据含糊不清.
- 没有实验证据证实了因果关系;一些研究表明潜在的治疗益处.
结论:
- 格利塔在膀癌发展中的作用仍然不确定.
- 需要进一步紧急调查glitazones在膀癌患者的潜在治疗益处.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
149
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
149
Dipeptidyl Peptidase 4 Inhibitors
155
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
155
Oral Hypoglycemic Agents: Glinides
127
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
127
Glucagon-like Receptor Agonists
289
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
289
Oral Hypoglycemic Agents: Sulfonylureas
176
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
176
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
141
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
141


